PURPOSE: Circulating tumor cells (CTCs) have been proved to be responsible for tumor metastasis and resistant to anticancer therapies. This study aims to isolate and characterize circulating tumor cells from human gastric cancer patients, and investigate characteristic differences between gastric CTCs and gastric cancer cell lines. METHODS: We analyzed 31 cases of gastric cancer patients using anti-CD45 antibody-conjugated magnetic microbeads negative separation, combined with fluorescence activated cell sorter CD44 positive screening. Abilities of tumor formation, metastasis, invasion, migration, irradiation and drug sensitivity of CTCs and gastric cancer cell lines were detected and compared. RESULTS: Of all the 31 patients, CD44(+)/CD45(-)CTCs were isolated in 14 patients, of which 3 cases were stage IIA, 2 cases stage IIB, 2 cases stage IIIC and 7 cases stage IV. The malignant behavior was demonstrated by both clonogenetic assay and tumor xenograft in nude mice. Compared with human gastric cancer cell lines, the migration and invasion abilities of CTCs increased to 3.21-12.6-fold and 2.3-6.7-fold, respectively (all p values <0.05). In addition, the metastatic potential of CTCs is much higher in vivo than that of the control. Furthermore, CTCs were found to be relatively sensitive to FU, cisplatin and paclitaxel, but relatively resistant to irradiation, oxaliplatin, cetuximab and trastuzumab. CONCLUSIONS: CD44(+)/CD45(-) gastric CTCs were isolated and found to exhibit stronger malignant behavior when compared with human gastric cancer cell lines. Furthermore, CTCs cultured in vitro have potential implications in drug sensitivity screening for the future anticancer treatments.
PURPOSE: Circulating tumor cells (CTCs) have been proved to be responsible for tumor metastasis and resistant to anticancer therapies. This study aims to isolate and characterize circulating tumor cells from humangastric cancerpatients, and investigate characteristic differences between gastric CTCs and gastric cancer cell lines. METHODS: We analyzed 31 cases of gastric cancerpatients using anti-CD45 antibody-conjugated magnetic microbeads negative separation, combined with fluorescence activated cell sorter CD44 positive screening. Abilities of tumor formation, metastasis, invasion, migration, irradiation and drug sensitivity of CTCs and gastric cancer cell lines were detected and compared. RESULTS: Of all the 31 patients, CD44(+)/CD45(-)CTCs were isolated in 14 patients, of which 3 cases were stage IIA, 2 cases stage IIB, 2 cases stage IIIC and 7 cases stage IV. The malignant behavior was demonstrated by both clonogenetic assay and tumor xenograft in nude mice. Compared with humangastric cancer cell lines, the migration and invasion abilities of CTCs increased to 3.21-12.6-fold and 2.3-6.7-fold, respectively (all p values <0.05). In addition, the metastatic potential of CTCs is much higher in vivo than that of the control. Furthermore, CTCs were found to be relatively sensitive to FU, cisplatin and paclitaxel, but relatively resistant to irradiation, oxaliplatin, cetuximab and trastuzumab. CONCLUSIONS:CD44(+)/CD45(-) gastric CTCs were isolated and found to exhibit stronger malignant behavior when compared with humangastric cancer cell lines. Furthermore, CTCs cultured in vitro have potential implications in drug sensitivity screening for the future anticancer treatments.
Authors: Vincent James Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Lauby-Secretan; Fatiha El Ghissassi; Véronique Bouvard; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Christopher P Wild Journal: J Natl Cancer Inst Date: 2011-12-12 Impact factor: 13.506
Authors: Elizabeth A Punnoose; Siminder K Atwal; Jill M Spoerke; Heidi Savage; Ajay Pandita; Ru-Fang Yeh; Andrea Pirzkall; Bernard M Fine; Lukas C Amler; Daniel S Chen; Mark R Lackner Journal: PLoS One Date: 2010-09-08 Impact factor: 3.240
Authors: Rebecca C Fitzgerald; Richard Hardwick; David Huntsman; Fatima Carneiro; Parry Guilford; Vanessa Blair; Daniel C Chung; Jeff Norton; Krishnadath Ragunath; J Han Van Krieken; Sarah Dwerryhouse; Carlos Caldas Journal: J Med Genet Date: 2010-07 Impact factor: 6.318
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Melody J Xu; Jay F Dorsey; Ravi Amaravadi; Giorgos Karakousis; Charles B Simone; Xiaowei Xu; Wei Xu; Erica L Carpenter; Lynn Schuchter; Gary D Kao Journal: Oncologist Date: 2015-11-27
Authors: Phung Thanh Huong; Sanjeev Gurshaney; Nguyen Thanh Binh; Anh Gia Pham; Huy Hoang Nguyen; Xuan Thanh Nguyen; Hai Pham-The; Phuong-Thao Tran; Khanh Truong Vu; Nhuong Xuan Duong; Claudio Pelucchi; Carlo La Vecchia; Paolo Boffetta; Hung D Nguyen; Hung N Luu Journal: Cancers (Basel) Date: 2020-03-15 Impact factor: 6.639